Supported by high quality clinical outcomes

The HORIZON study (in combination with cataract surgery): The largest, prospective, randomized, controlled MIGS pivotal trial to date

The first MIGS pivotal trial to enroll patients globally—556 patients at 38 centers in 9 countries
Clinical outcomes showed the largest improvement compared to cataract surgery alone for IOP reduction and medication elimination of any MIGS pivotal trial at 24 months.1-4,*

Hydrus Microstent treatment led to long-term IOP reduction

Proven, durable outcomes1
Compared to results with cataract surgery alone, the Hydrus Microstent treatment effect showed increased benefits from year 1 to year 2.

Treatment effect in the Hydrus Microstent group improved from year 1 to year 2 compared to cataract surgery alone.1

The Hydrus Microstent – delivering a new confidence in the treatment of mild to moderate primary open-angle glaucoma:

Superior long-term IOP reduction and glaucoma drop elimination

Clinically proven, 2-year outcomes showing the largest improvement compared to control for IOP reduction and elimination of glaucoma medication reported in a MIGS pivotal trial.1-4,*

Proven, durable outcomes

Treatment effect in the Hydrus Microstent group improved from year 1 to year 2 compared to cataract surgery alone.­1

Outstanding safety profile

Safety profile comparable with cataract surgery alone and other canal-based MIGS procedures.2-5,*

Straightforward and efficient microstent delivery

Intuitive delivery system allows for a straightforward procedure with minimal learning curve and no need to target collector channels or implant multiple devices.1,6

See the Hydrus Microstent's performance in The COMPARE Study.

Please Select Your Country

Continue